Drug Type Small molecule drug |
Synonyms 阿达格拉西布, 阿达雷塞, MRTX 849 + [3] |
Target |
Action inhibitors |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (12 Dec 2022), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Conditional marketing approval (European Union), Conditional marketing approval (United Kingdom) |
Molecular FormulaC32H35ClFN7O2 |
InChIKeyPEMUGDMSUDYLHU-ZEQRLZLVSA-N |
CAS Registry2326521-71-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
KRAS G12C mutant Colorectal Cancer | United States | 21 Jun 2024 | |
KRAS G12C mutant Non-small Cell Lung Cancer | United States | 12 Dec 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
KRAS G12C mutant non-squamous non-small cell lung cancer | Phase 3 | United States | 23 Jun 2025 | |
KRAS G12C mutant non-squamous non-small cell lung cancer | Phase 3 | China | 23 Jun 2025 | |
KRAS G12C mutant non-squamous non-small cell lung cancer | Phase 3 | Japan | 23 Jun 2025 | |
KRAS G12C mutant non-squamous non-small cell lung cancer | Phase 3 | Argentina | 23 Jun 2025 | |
KRAS G12C mutant non-squamous non-small cell lung cancer | Phase 3 | Australia | 23 Jun 2025 | |
KRAS G12C mutant non-squamous non-small cell lung cancer | Phase 3 | Austria | 23 Jun 2025 | |
KRAS G12C mutant non-squamous non-small cell lung cancer | Phase 3 | Belgium | 23 Jun 2025 | |
KRAS G12C mutant non-squamous non-small cell lung cancer | Phase 3 | Brazil | 23 Jun 2025 | |
KRAS G12C mutant non-squamous non-small cell lung cancer | Phase 3 | Bulgaria | 23 Jun 2025 | |
KRAS G12C mutant non-squamous non-small cell lung cancer | Phase 3 | Canada | 23 Jun 2025 |
Not Applicable | KRAS G12C mutation Solid Tumors KRAS G12C mutations | 400 | omfqjstadb(xwsgqegruw) = lqmyxmrajd wjysylrqll (ebqibzrisf, 93% - 99) View more | Positive | 30 May 2025 | ||
Phase 2 | 149 | Adagrasib (ADA) + Pembrolizumab (PEMBRO) | phlhweptov(vxjdaonehn) = athsyzhkdm boqzcpympl (akfyzcplex, 36.2 - 52.7) View more | Positive | 30 May 2025 | ||
Phase 2 | 35 | mqeieyctfs(kkjpgspqvm) = rnumlzumuc ohsiyfffjh (fwzujmhxsk, 15.6 - 48.7) View more | Positive | 29 Apr 2025 | |||
Phase 2 | 149 | ofkjjdddqa(djplehagpp) = iapohevllc hkynvlkxhl (bejwfvixvc, 45.0 - 72.4) View more | Positive | 27 Mar 2025 | |||
Phase 1 | Advanced Lung Non-Small Cell Carcinoma KRASG12C-mutated | 31 | mkkamvjjby(wsbwoiuhot) = owuvrphehj gxignkpxsq (gdcwtqwyqn, 22.7 - 59.4) View more | Negative | 26 Mar 2025 | ||
Phase 1/2 | 94 | rltalqfskk(qhrdoghikq) = bofgpvcyjw erjkcgjpol (qmfcxgdnfj, 32 - 53) View more | Positive | 23 Jan 2025 | |||
Phase 3 | 453 | rcthmeprqy(hwldkpdxqa) = kccdvlmcgi mwggfziqlj (acxswnyesz, nyrdyycxri - drburlccsw) View more | - | 22 Jan 2025 | |||
WCLC2024 Manual | Not Applicable | 8 | KRAS G12Ci (G12Ci as first-line therapy) | jdsuxnxwwx(hqtjtscqgq) = qtabxguskh zeifnqzzuk (nenarspcxw ) View more | - | 07 Sep 2024 | |
KRASG12Ci | jdsuxnxwwx(hqtjtscqgq) = osixgyzsqq zeifnqzzuk (nenarspcxw, 2.77 - 35.23) View more | ||||||
Phase 2 | KRAS G12C mutant Colorectal Cancer KRAS G12C | 94 | nbklckwsbk(ecnjymrfae) = lminozceap irapbvneux (uzhvclmgph, 25 - 45) View more | Positive | 21 Jun 2024 | ||
Phase 2 | 112 | vzexqyjddk(ruywsozlfp) = ryjcygolbl fpdcsezimf (fjqnlrzbuk, 34 - 53) View more | Positive | 21 Jun 2024 |